N.E.W. Advisory Services’s Standard BioTools LAB Stock Holding History

N.E.W. Advisory Services’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-530	Closed	-$678	–	938
2025 Q4	$678	Hold	530	–	–	﹤0.01%	874
2025 Q3	$689	Hold	530	–	–	﹤0.01%	822
2025 Q2	$636	Hold	530	–	–	﹤0.01%	827
2025 Q1	$572	Buy	+530	New	+$744	﹤0.01%	891

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

N.E.W. Advisory Services's LAB Position: Q1 2026 in Review

N.E.W. Advisory Services sold out of Standard BioTools (LAB) in Q1 2026, closing a stake of 530 shares — an estimated $678 sold.

N.E.W. Advisory Services first reported a position in LAB in Q1 2025 and held it in 4 quarters. The position peaked at $689 in Q3 2025. 156 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

N.E.W. Advisory Services reported no remaining Standard BioTools position as of Q1 2026 after selling out during the quarter.
N.E.W. Advisory Services sold 530 Standard BioTools shares in Q1 2026, an estimated $678.
N.E.W. Advisory Services first reported a position in Standard BioTools in Q1 2025 and held it in 4 quarters.
N.E.W. Advisory Services's Standard BioTools position peaked at $689 in Q3 2025.
156 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on N.E.W. Advisory Services's 13F filing for Q1 2026, filed 5 May 2026.